E28-Brolucizumab for wet AMD (HAWK and HARRIER)- Dr. Pravin Dugel

Dr. Dugel discusses 1 and 2 year results of HAWK and HARRIER on Brolucizumab for neovascular AMD. Full reference: Dugel, P. U., Koh, A., Ogura, Y., Jaffe, G. J., Schmidt-Erfurth, U., Brown, D. M., . . . Investigators, H. S. (2019). HAWK and HARRIER: Phase 3, Multicenter, Randomized, Double-Masked Trials of Brolucizumab for Neovascular Age-Related Macular Degeneration. Ophthalmology. doi:10.1016/j.ophtha.2019.04.017

Episode metadata supplied by the publisher feed · Published Sep 2, 2019

Embed this episode

Attribution link and audio player

NOW PLAYING

E28-Brolucizumab for wet AMD (HAWK and HARRIER)- Dr. Pravin Dugel

0:00 19:55

1×

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Share this episode

Similar Episodes

No similar episodes found.

Similar Podcasts

No similar podcasts found.

Frequently Asked Questions

How long is this episode of The Retina Channel Podcast?

This episode is 19 minutes long.

When was this The Retina Channel Podcast episode published?

This episode was published on September 2, 2019.

Can I download this The Retina Channel Podcast episode?

Yes. Use the download control on the episode player to save the publisher-provided media file.

URL copied to clipboard!